Payment overview · 2025
General Payments
$1,410.74
57 reported records · 22 companies
Healthcare provider profile · identity verified
Esther Patsy Mihindu, DO
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · DALLAS, TX · NPI 1104116136
Verified facts
What the public records show
CMS Open Payments records show Esther Patsy Mihindu, DO received $1,410.74 in general payments during 2025 across 57 reported records.
Boston Scientific Corporation accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $251.40 | 17.8% | 11 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $248.45 | 17.6% | 15 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $145.08 | 10.3% | 2 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $122.14 | 8.7% | 4 | 2025 |
| Koya Medical, Inc. | Unresolved — no canonical attribution shown | $111.07 | 7.9% | 2 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $63.30 | 4.5% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $57.58 | 4.1% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $51.56 | 3.6% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $36.24 | 2.6% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $36.01 | 2.5% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $34.57 | 2.5% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $30.46 | 2.2% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $29.13 | 2.1% | 1 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $27.63 | 2.0% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $27.38 | 1.9% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $24.42 | 1.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.56 | 1.5% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $20.30 | 1.4% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $20.03 | 1.4% | 1 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $19.47 | 1.4% | 1 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $17.36 | 1.2% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $16.60 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,410.74 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $127.03 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $122.14 | 4 | 2025 |
Source payment records
|
|||||
| DAYSPRING Normalized: dayspring |
Device | Koya Medical, Inc. | $111.07 | 2 | 2025 |
Source payment records
|
|||||
| KOYA MEDICAL Normalized: koya medical |
Device | Koya Medical, Inc. | $111.07 | 2 | 2025 |
Source payment records
|
|||||
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $63.30 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $57.58 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $57.58 | 3 | 2025 |
Source payment records
|
|||||
| General - Thrombectomy Normalized: general thrombectomy |
Device | Boston Scientific Corporation | $51.63 | 2 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $36.01 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $34.57 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $29.13 | 1 | 2025 |
Source payment records
|
|||||
| Express LD Iliac / Biliary Normalized: express ld iliac biliary |
Device | Boston Scientific Corporation | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| RESTOREFLOW Normalized: restoreflow |
Device | LeMaitre Vascular, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 197 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 79 |
| Eliquis | Apixaban | 66 | 22 |
| Cilostazol | Cilostazol | 40 | 12 |
| Xarelto | Rivaroxaban | 35 | 13 |
| Gabapentin | Gabapentin | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Diazepam | Diazepam | 20 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Tramadol Hcl | Tramadol Hcl | 17 | 13 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,410.74 · 57 records | Boston Scientific Corporation | AFX2 Bifurcated Endograft System, AQUACEL AG+ EXTRA, ARTIX MT, Alto Abdominal Stent Graft System, AngioJet Ultra 5000A, CGuard Prime Carotid Stent System, COLLAGENASE SANTYL, DAYSPRING, EVARREST, Express LD Iliac / Biliary, FLOWRUNNER, Flexitouch Plus, General - Atherectomy, General - Thrombectomy, General - Vascular Intervention, JETSTREAM SC, KOYA MEDICAL, Kerecis GraftGuide, Kerecis SurgiClose, Labosys, Nimbl, RESTOREFLOW, Ranger, Restrata Wound Matrix, RotarexS 6 F x 135 cm, SURGIFLO Hemostatic Matrix, Serrantor, TheraGenesis Wound Matrix, URGOCLEAN AG | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error